Fate Therapeutics, Inc. (NasdaqGM: FATE)
Health Care · Biotechnology · US
$2.18
-6.03% today · +56.8% 1Y
Fate Therapeutics, Inc. (NasdaqGM: FATE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $261.21M and employs 161 people.
Over the last twelve months the share price has gained 56.8%, trading between 0.95 and 3.23.
Tweenvest scores Fate Therapeutics, Inc. across four factors: quality 36/100, value 45/100, growth 0/100. Its strongest factor is value.
FATE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $261.21M
- Revenue (TTM)
- $6.49M
- P/E
- —
- EPS
- -1.05
- Dividend yield
- —
- Beta (5Y)
- 2.53
- 52-week high
- $3.23
- 52-week low
- $0.95
- Avg volume (3M)
- —
- Shares outstanding
- 119.82M
- Employees
- 161
- Next earnings
- —
About Fate Therapeutics, Inc.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
- ISIN
- US31189P1021
- Founded
- 2007
- Listed since
- Oct 1, 2013
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Inventage Lab, Inc.KOSDAQ: A389470 | $263.31M | ₩26,600.00 | -6.01% |
| Santhera Pharmaceuticals Holding AGSWX: SANN | $263.01M | CHF14.28 | -5.56% |
| Obigen Pharma Inc.TPEX: 7876 | $262.25M | NT$78.20 | +21.81% |
| Anika Therapeutics, Inc.NasdaqGS: ANIK | $262.04M | $19.58 | +1.82% |
| VISEN PharmaceuticalsSEHK: 2561 | $259.19M | HK$18.61 | +0.59% |
| Healios K.K.TSE: 4593 | $258.52M | ¥302.00 | +5.23% |
| Upstream Bio, Inc.NasdaqGS: UPB | $257.42M | $4.70 | -6.75% |
| PharmaEngine, Inc.TPEX: 4162 | $257.02M | NT$57.20 | +3.25% |
Figures last refreshed Oct 11, 2026.